Six-month humoral response to mRNA SARS-CoV-2 vaccination in patients with multiple sclerosis treated with ocrelizumab and fingolimod
Rocco Capuano, Alvino Bisecco, Miriana Conte, Giovanna Donnarumma, Manuela Altieri, Elena Grimaldi, Gianluigi Franci, Annalisa Chianese, Massimiliano Galdiero, Nicola Coppola, Gioacchino Tedeschi, Antonio Gallo
Topics & Concepts
MedicineOcrelizumabFingolimodMultiple sclerosisImmunologyAntibody responseAntibodyVaccinationNeutralizing antibodyPopulationEnvironmental healthRituximabMultiple Sclerosis Research StudiesPeripheral Neuropathies and DisordersSARS-CoV-2 and COVID-19 Research